INTR News

Intrinsic Therapeutics Announces the First Implantation of the Barricaid® Annular Closure Device Under Awake Sedation

(NASDAQ:INTR) BOSTON, Sept. 2, 2025 /PRNewswire/ -- Intrinsic Therapeutics, Inc., a medical technology company committed to redefining the standard of care for lumbar discectomy patients with large annular defects by reducing reoperations for reherniations by 81%* with its Barricaid Annular Closure...

September 2, 2025Device Launch

Inter named as a “Most Honored Company”

INTR

MIAMI, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Inter&Co Inc. (NASDAQ: INTR | B3: INBR32) has been recognized by Extel (formerly Institutional Investor) as a public-listed bank with standout management and investor relations. Inter earned “Most Honored Company” and was placed in several categories within the mid-cap financials sector, based on combined buy- and sell-side votes:

August 26, 2025Awards

Inter & Co Q1 GAAP EPS $0.11 Misses $0.12 Estimate, Sales $313.81M Miss $327.02M Estimate

INTR

May 12, 2025

Morgan Stanley Maintains Underweight on Inter & Co, Lowers Price Target to $4

INTR

March 17, 2025

Inter & Co Q4 Sales $340.00M Beat $314.68M Estimate

INTR

November 14, 2024

Itau BBA Upgrades Inter & Co to Outperform, Announces $8 Price Target

INTR

May 21, 2024